Myeloproliferative Disorder: Clinical Trials

10 trials for Myeloproliferative Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 active not recruiting, 1 recruiting. 10 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 8, Active not recruiting 1, Recruiting 1
Phase 11Completed 1

Follow Myeloproliferative Disorder: new trials by email Literature Review of Myeloproliferative Disorder trials Research Report on Myeloproliferative Disorder

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cord Blood Transplant in Adults With Blood Cancers
Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center172023-05-222026-10-23
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Thymoglobulin, Melphalan, Fludarabine - Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes
Phase 2RecruitingUniversity of Liege1142019-02-042022-10-12
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 2CompletedStanford University222018-11-052023-12-12
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 2CompletedMemorial Sloan Kettering Cancer Center462018-02-072026-05-26
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Isavuconazole - Hematologic Malignancy, Myeloproliferative Disorder
Phase 2CompletedMemorial Sloan Kettering Cancer Center992017-05-042025-05-16
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Graft Manipulation (CD34+ Selection) - MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder
Phase 1 / Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)412013-05-292020-07-21
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
IL-2 - Acute Lymphoblastic Leukemia, ALL
Phase 2CompletedBaylor College of Medicine252007-06-012018-05-04
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Bevacizumab, Carboplatin, Gemcitabine - Myeloproliferative Disorder, Urothelial Carcinoma
Phase 2CompletedMemorial Sloan Kettering Cancer Center512006-05-012016-01-22
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF - AML, ALL
Phase 2CompletedBeth Israel Deaconess Medical Center252002-12-012016-07-18
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Fludarabine, Melphalan, Stem cells - Acute Myelogenous Leukemia, Lymphoid Leukemia
Phase 2CompletedUniversity of Chicago2042001-11-012016-11-22

Narrower conditions

Myeloproliferative Disorders (10)  ·  Myelodysplastic Syndromes (8)  ·  Lymphoma, Non-Hodgkin (7)  ·  Hodgkin Disease (6)  ·  Leukemia, Myeloid, Acute (6)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Anemia, Aplastic (2)  ·  Hematologic Neoplasms (2)  ·  Multiple Myeloma (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Blast Crisis (1)  ·  Carcinoma, Transitional Cell (1)  ·  Graft vs Host Disease (1)

Broader conditions

Bone Marrow Diseases (10)  ·  Hematologic Diseases (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Neoplasms (9)  ·  Neoplasms by Histologic Type (9)  ·  Immune System Diseases (8)  ·  Immunoproliferative Disorders (8)  ·  Lymphatic Diseases (8)  ·  Lymphoproliferative Disorders (8)  ·  Lymphoma (7)  ·  Leukemia (6)  ·  Leukemia, Lymphoid (6)  ·  Leukemia, Myeloid (6)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)

Interventions

fludarabine (3)  ·  Alemtuzumab (2)  ·  Cyclophosphamide (2)  ·  Cyclosporine (2)  ·  Melphalan (2)  ·  Mycophenolic Acid (2)  ·  Whole-Body Irradiation (2)  ·  Antilymphocyte Serum (1)  ·  Bevacizumab (1)  ·  Carboplatin (1)  ·  Filgrastim (1)  ·  Gemcitabine (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Interleukin-2 (1)

Sponsors

Memorial Sloan Kettering Cancer Center (4)  ·  Baylor College of Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Stanford University (1)  ·  University of Chicago (1)  ·  University of Liege (1)

Countries

United States (9)  ·  Belgium (1)

Top investigators

Andrew Artz, MD (1)  ·  Ann Jakubowski, MD (1)  ·  David E Avigan, MD (1)  ·  David F McDermott, MD (1)  ·  Dean Bajorin, MD (1)  ·  Ioannis Politikos, MD (1)  ·  Rayne Rouce, MD (1)  ·  Robert Lowsky, MD (1)  ·  Sawa Ito, M.D. (1)

Results publications

PMID 24573552, PMID 40423982

NIH funding

2017 (1)